GR20000100145A - Μεσον για την αυξηση της απελευθερωσης ακετυλχολινης στον εγκεφαλο - Google Patents

Μεσον για την αυξηση της απελευθερωσης ακετυλχολινης στον εγκεφαλο

Info

Publication number
GR20000100145A
GR20000100145A GR20000100145A GR2000100145A GR20000100145A GR 20000100145 A GR20000100145 A GR 20000100145A GR 20000100145 A GR20000100145 A GR 20000100145A GR 2000100145 A GR2000100145 A GR 2000100145A GR 20000100145 A GR20000100145 A GR 20000100145A
Authority
GR
Greece
Prior art keywords
anisoyl
acetylcholic
enhances
brain
release
Prior art date
Application number
GR20000100145A
Other languages
English (en)
Other versions
GR1003591B (el
Inventor
Masatoshi Shirane
Yushiro Tanaka
Kazuo Nakamura
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of GR20000100145A publication Critical patent/GR20000100145A/el
Publication of GR1003591B publication Critical patent/GR1003591B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στην χρήση Ν-ανισοϋλ-γ-αμινο-βουτυρικού οξέος (Ν-ανισοϋλ-GABA) ή π-ανισικού οξέος για την παρασκευή μίας φαρμακευτικής σύνθεσης που αυξάνει την απελευθέρωση ακετυλχολίνης (ACh) στον εγκέφαλο. Ειδικότερα, η εφεύρεση αναφέρεται στην χρήση Ν-ανισοϋλ-GABA ή π-ανισικού οξέος για την θεραπευτική αγωγή διαταραχών του κιρκάνιου ρυθμού, διαταραχών του ύπνου, διαταραχών με έλλειψη προσοχής και προβληματικών συμπεριφορών. Η εφεύρεση αναφέρεται επίσης σε φαρμακευτικές συνθέσεις που περιέχουν Ν-ανισοϋλ-GABA ή π-ανισικό οξύ ως αποτελεσματικό συστατικό.ΰ
GR20000100145A 1999-04-27 2000-04-24 Μεσον για την αυξηση της απελευθερωσης ακετυλχολινης στον εγκεφαλο. GR1003591B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99108223 1999-04-27

Publications (2)

Publication Number Publication Date
GR20000100145A true GR20000100145A (el) 2000-12-29
GR1003591B GR1003591B (el) 2001-05-22

Family

ID=8238054

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000100145A GR1003591B (el) 1999-04-27 2000-04-24 Μεσον για την αυξηση της απελευθερωσης ακετυλχολινης στον εγκεφαλο.

Country Status (24)

Country Link
US (1) US20030073744A1 (el)
JP (1) JP2000309529A (el)
KR (1) KR100372906B1 (el)
CN (1) CN1277019A (el)
AR (1) AR023763A1 (el)
AT (1) AT408836B (el)
AU (1) AU3011300A (el)
BE (1) BE1013314A3 (el)
BR (1) BR0002381A (el)
CA (1) CA2307022A1 (el)
DE (1) DE10020237A1 (el)
DK (1) DK200000687A (el)
ES (1) ES2176078A1 (el)
FI (1) FI20000977A (el)
FR (1) FR2792833B1 (el)
GB (1) GB2351662A (el)
GR (1) GR1003591B (el)
IE (1) IE20000308A1 (el)
IT (1) IT1318490B1 (el)
NL (1) NL1015043C2 (el)
PT (1) PT102456B (el)
SE (1) SE0001499L (el)
TR (1) TR200001133A2 (el)
ZA (1) ZA200002041B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5273731B2 (ja) * 2009-08-11 2013-08-28 独立行政法人産業技術総合研究所 生体リズムの制御剤
CA3119517C (en) * 2018-11-13 2023-08-22 Xianfeng PENG Use of acylated derivative of amino acid in preparing animal feed additive

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005143A1 (de) * 1978-02-10 1979-11-14 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft 1-Benzoyl-2-pyrrolidinonderivat, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel
JPH1081607A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk 抗菌剤
JPH1081626A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk チロシナーゼ活性阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0005143A1 (de) * 1978-02-10 1979-11-14 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft 1-Benzoyl-2-pyrrolidinonderivat, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel
JPH1081607A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk 抗菌剤
JPH1081626A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk チロシナーゼ活性阻害剤

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HIRATA, KAZUNARI ET AL: "Effects of metabolites of aniracetam on long-term potentiation in mossy fiber-CA3 synapses in the rat hippocampal slices", XP002157120, retrieved from STN Database accession no. 122:96241 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAMIYAMA, HIROSHI: "Antimicrobial agents containing 4-substituted benzoic acids", XP002157121, retrieved from STN Database accession no. 128:243168 *
DATABASE WPI Section Ch Week 199823, Derwent World Patents Index; Class B03, AN 1998-255479, XP002157122 *
GRAZIA GIOVANNINI, MARIA ET AL: "Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo.", DRUG DEVELOPMENT RESEARCH, (1993) VOL. 28, NO. 4, PP. 503-509., XP000978572 *
KIMURA, M. (1) ET AL: "An acetylcholine releaser, aniracetam, restores REM sleep impairment in stroke-prone spontaneous hypertensive rats.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., (1999) VOL. 25, NO. 1-2, PP. 2144. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE. MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 SOCIETY FOR NEUROSCIENCE., XP000979635 *
NAKAMURA K ET AL: "Activation of the reticulothalamic cholinergic pathway by the major metabolites of aniracetam.", EUROPEAN JOURNAL OF PHARMACOLOGY, (1999 SEP 10) 380 (2-3) 81-9., XP000978536 *
NAKAMURA K ET AL: "Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam.", EUROPEAN JOURNAL OF PHARMACOLOGY, (1998 JAN 26) 342 (2-3) 127-38., XP000978537 *
NAKAMURA K. ET AL: "Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam.", DRUG DEVELOPMENT RESEARCH, (1998) 43/2 (85-97)., XP000978544 *
NAKAMURA, KAZUO (1) ET AL: "Palliative action of aniracetam on central serotonergic abnormalities revealed as performance impairments in a choice reaction task in rats.", JAPANESE JOURNAL OF PHARMACOLOGY, (1999) VOL. 79, NO. SUPPL. 1, PP. 240P. MEETING INFO.: 72ND ANNUAL MEETING OF THE JAPANESE PHARMACOLOGICAL SOCIETY SAPPORO, JAPAN MARCH 22-25, 1999 JAPANESE PHARMACOLOGICAL SOCIETY., XP000979606 *
OGISO, TARO ET AL: "Pharmacokinetics of Aniracetam and Its Metabolites in Rats", J. PHARM. SCI. (1998), 87(5), 594-598, XP000971998 *
SHIRANE M ET AL: "Group II metabotropic glutamate receptors are a common target of N- anisoyl - GABA and 1S,3R-ACPD in enhancing ACh release in the prefrontal cortex of freely moving SHRSP.", NEUROPHARMACOLOGY, (2000 MAR 3) 39 (5) 866-72., XP000978535 *
SHIRANE, M. ET AL: "N- anisoyl - GABA -induced acetylcholine release in the brain of SHRSP and possible involvement of group II metabotropic glutamate receptors", INT. CONGR. SER. (2000), 1200(FRONTIERS OF THE MECHANISMS OF MEMORY AND DEMENTIA), 205-206, XP000978533 *
TANAKA Y. ET AL: "Aniracetam attenuates the 5-HT2 receptor-mediated head-twitch response in rodents as a hallucination model.", DRUG DEVELOPMENT RESEARCH, (1998) 44/4 (131-139)., XP000978543 *
YAKURI TO CHIRYO (1994), 22(4), 1837-43 *

Also Published As

Publication number Publication date
SE0001499D0 (sv) 2000-04-26
SE0001499L (sv) 2000-10-28
NL1015043A1 (nl) 2000-10-30
FR2792833B1 (fr) 2002-09-06
BE1013314A3 (fr) 2001-11-06
AU3011300A (en) 2000-11-02
KR100372906B1 (ko) 2003-02-17
CA2307022A1 (en) 2000-10-27
ES2176078A1 (es) 2002-11-16
BR0002381A (pt) 2000-11-07
FR2792833A1 (fr) 2000-11-03
JP2000309529A (ja) 2000-11-07
DK200000687A (da) 2000-10-28
ITMI20000914A0 (it) 2000-04-21
ATA7162000A (de) 2001-08-15
GR1003591B (el) 2001-05-22
US20030073744A1 (en) 2003-04-17
CN1277019A (zh) 2000-12-20
DE10020237A1 (de) 2001-02-08
GB0010049D0 (en) 2000-06-14
TR200001133A2 (tr) 2000-11-21
IE20000308A1 (en) 2000-11-29
FI20000977A0 (fi) 2000-04-26
IT1318490B1 (it) 2003-08-25
AR023763A1 (es) 2002-09-04
GB2351662A (en) 2001-01-10
KR20010029658A (ko) 2001-04-06
AT408836B (de) 2002-03-25
NL1015043C2 (nl) 2001-03-30
ZA200002041B (en) 2000-10-27
FI20000977A (fi) 2000-10-27
PT102456A (pt) 2000-11-30
ITMI20000914A1 (it) 2001-10-21
PT102456B (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
YU25399A (sh) 6-fenilpiridil-2-amino derivati korisni kao nos inhibitori
DE60207383D1 (de) Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
BR0317888A (pt) Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
NO20052490D0 (no) Dagsdoseringsenheter for melatonin.
GB0111186D0 (en) Novel compounds
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
NZ513096A (en) Compositions for treating inflammatory response
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
MX9501849A (es) Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos.
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
GEP20043267B (en) Adenosine Receptor Antagonists, Methods of Making and Using the Same
GR3036408T3 (en) Benzofuran-acrylic acid derivatives and their use as modulators of rxrs or rars receptors
UY26426A1 (es) Nuevos compuestos
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
GR1003591B (el) Μεσον για την αυξηση της απελευθερωσης ακετυλχολινης στον εγκεφαλο.
AU2002224847A1 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
HUP0301578A3 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
TW200510399A (en) 1, 3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
MXPA04006457A (es) Alcanosulfonamidas novedosas como antagonistas de endotelina.